PharmaDrug Inc (CSE:BUZZ) (OTCMKTS:LMLLF) Daniel Cohen tells Proactive it is the first company to receive Orphan Drug Designation for its dimethyltryptamine (DMT) formulation to prevent ischemia-reperfusion injury from organ transplantation from the FDA. Cohen says the designation covers solid organ transplantation, which includes the liver, kidney, heart and lungs. The drug designation is broader than its original application, which was for kidney transplantation only.
PharmaDrug is first company to receive Orphan Drug Designation for DMT from the FDA
